SuperworthOaktree Acquisition Corp. III Life Sciences EPS OACC
Diluted earnings per share by quarter and over the last twelve months, from 2024.
- Last 12 months, to Jun 30, 2026
- $0.54
- Latest quarter, Q2 FY26
- $0.07
- −13% on a year earlier
- Fiscal year 2025
- $0.56
Oaktree Acquisition Corp. III Life Sciences' earnings per share was $0.54 over the twelve months to Jun 30, 2026, up 32% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.07, down 12% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.56 | n/a |
| FY2024 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.07 | −13% | $0.54 | |
| Q1 FY26 | $0.06 | −14% | $0.55 | |
| Q4 FY25 | $0.33 | +22% | $0.56 | |
| Q3 FY25 | $0.08 | n/a | $0.50 | |
| Q2 FY25 | $0.08 | n/a | $0.41 | |
| Q1 FY25 | $0.07 | n/a | n/a | |
| Q4 FY24 | $0.27 | n/a | n/a | |
| Q3 FY24 | −$0.01 | n/a | n/a |
Against its peers
Companies in Financial Services nearest Oaktree Acquisition Corp. III Life Sciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| OACCOaktree Acquisition Corp. III Life Sciences | $0.54 | |
| RMBIRichmond Mutual Bancorporation | $1.21 | +29% a year |
| NKSHNational Bankshares | $3.18 | +80% a year |
| VABKVirginia National Bankshares | $4.56 | +38% a year |
| FXNCFirst National | $2.40 | +140% a year |
| HWBKHawthorn Bancshares | $3.67 | +24% a year |
| EFSIEagle Financial Services | $3.46 | +60% a year |
| GBFHGBank Financial | $1.28 | −7% a year |
| FNRNFirst Northern Community Bancorp | $1.35 | +13% a year |
| SNFCASecurity National Financial | $1.44 | +40% a year |
| WNEBWestern New England Bancorp | $0.84 | +42% a year |
| Peer median | $1.92 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Oaktree Acquisition Corp. III Life Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.